Internal Medicine · Buena Park, CA
NPI
1487627261
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
5832 Beach Blvd Unit 214
Buena Park, CA, 90621
Phone (714) 523-7575
Groups this clinician bills Medicare through
Medicare paid, 2024
$165K
2,508 services
Medicare patients, 2024
379
Average age 79
Drug cost, 2024
$4.7M
35,105 prescriptions
Company payments, 2025
$2,128
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul S Chang was code 99213 (office e&m - established), 843 times for 348 patients. In total Paul S Chang billed 2,508 services in 45 codes, and Medicare paid $165K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-02-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 843 | 348 | $60.06 | $51K |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 283 | 283 | $140.02 | $40K |
| 99214 Office E&M - Established | Office | 176 | 137 | $105.34 | $19K |
| G0008 Administration of influenza virus vaccine | Office | 173 | 172 | $29.40 | $5,086 |
| 90653 Vaccine Product | Office | 149 | 149 | $81.82 | $12K |
| 99212 Office E&M - Established | Office | 111 | 79 | $40.98 | $4,548 |
| 82044 Clinical Chemistry | Office | 107 | 105 | $6.11 | $654 |
| J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | Office | 78 | 13 | $51.42 | $4,011 |
| 20610 Joint Injection | Office | 78 | 13 | $51.82 | $4,042 |
| 96372 Injection Administration | Office | 65 | 40 | $10.29 | $669 |
| 81003 Clinical Chemistry | Office | 55 | 46 | $2.20 | $121 |
| 76700 Ultrasound - Abdomen and Pelvis | Office | 51 | 47 | $87.97 | $4,486 |
| 93000 Electrocardiogram | Office | 43 | 37 | $10.69 | $460 |
| 99497 Care Management/Coordination | Office | 36 | 36 | $65.78 | $2,368 |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 32 | 25 | $42.40 | $1,357 |
By year: 2022 $223K for 3,738 services; 2023 $191K for 3,041 services; 2024 $165K for 2,508 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82044 Clinical Chemistry | 107 | 105 | $6.11 | $654 |
| 81003 Clinical Chemistry | 55 | 46 | $2.20 | $121 |
Medicare prescription drug claims, 2024
In 2024, the drug Paul S Chang prescribed most often to Medicare patients was Rosuvastatin Calcium, with 2,883 prescriptions and refills. In total Paul S Chang wrote 35,105 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 2,883 | 7,320 | 737 | $30K |
| Losartan Potassium Generic | 2,384 | 5,917 | 577 | $19K |
| Atorvastatin Calcium Generic | 2,285 | 5,576 | 538 | $19K |
| Amlodipine Besylate Generic | 2,150 | 5,230 | 505 | $8,927 |
| Metformin Hcl Generic | 1,712 | 3,983 | 396 | $9,279 |
| Tamsulosin Hcl Generic | 997 | 2,360 | 236 | $9,926 |
| Vascepa Icosapent Ethyl | 925 | 1,267 | 156 | $430K |
| Omeprazole Generic | 873 | 1,533 | 335 | $5,584 |
| Jardiance Empagliflozin | 737 | 1,081 | 127 | $626K |
| Metoprolol Succinate Generic | 602 | 1,458 | 147 | $6,853 |
| Finasteride Generic | 539 | 1,289 | 131 | $4,464 |
| Fluticasone Propionate Generic | 520 | 794 | 163 | $5,161 |
| Montelukast Sodium Generic | 506 | 906 | 110 | $3,102 |
| Creon Lipase/Protease/Amylase | 493 | 589 | 113 | $584K |
| Memantine Hcl Generic | 484 | 941 | 111 | $8,425 |
Brand drugs: 6,169 claims; generic drugs: 28,708 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul S Chang $2,128 ($2,128 in general payments such as food, travel and fees) from 22 companies. The largest payer was Abbvie Inc. with $313.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 15 | $313 |
| Amgen Inc. AMGN | 29 | $243 |
| Ardelyx, Inc. ARDX | 7 | $189 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $188 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 10 | $177 |
| Merck Sharp & Dohme LLC MRK | 5 | $139 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $113 |
| GlaxoSmithKline, LLC. GSK | 5 | $107 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $87.68 |
| Sumitomo Pharma America, Inc. 4506.T | 3 | $79.33 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.